Launch Tx provides biotech and biopharma companies with solutions that speed drug candidates’ path to market and connection with investors that provide development funding. Bridging expertise in regulatory strategy, clinical development, clinical operations, manufacturing, and commercialization, we forge a powerfully aligned team focused on the finish.
Launch Tx offers a spectrum of custom-tailored collaboration models, from advisory services to complete operational execution. We provide access to innovative technologies and strategic vendor relationships, minimizing risks and optimizing development.
Launch Tx is backed by leading investors, Carlyle and its life sciences franchise, Abingworth. Launch Tx was formed in 2022 with the vision of assembling an exceptional team that could redefine late-stage development. The goal? Expediting the pathway for therapies to be approved, and ultimately, delivered to the patients who need them.
Company Details
- Employees
- 41
- Founded
- -
- Address
- 420 Boylston Street,
- Industry
- Biotechnology
- Website
- https://launchtx.com/
- HQ
- Boston, Massachusetts
Launch Therapeutics Questions
Launch Therapeutics's website is https://launchtx.com/
Launch Therapeutics's LinkedIn profile is https://www.linkedin.com/company/launch-therapeutics
Launch Therapeutics has
41 employees.
View email and phone details for 41
employees at Launch Therapeutics.
Launch Therapeutics's industry is
Biotechnology
Launch Therapeutics's top competitors are
Orsini - Rare Disease Pharmacy Solutions,
Ocular Therapeutix, Inc.,
Eyepoint,
Opthea,
Ppd,
Soleus Capital Management, L.p.,
Abingworth,
Trinetx,
Fortrea,
The Carlyle Group.
Launch Therapeutics's categories are Biotechnology
Launch Therapeutics's founding year is 2022
